Abstract
Dual antiplatelet therapy forms currently the basis in acute coronary syndrome pharmacological treatment. However, there is a wide variability in antiplatelet response to clopidogrel, which may lead to antiplatelet therapy insufficient efficacy and subsequent risk of thrombotic events. Laboratory monitoring of antiplatelet therapy may help to identify patients with insufficient antiplatelet response. We discuss the benefits of routine monitoring of antiplatelet therapy in clinical practice.
Highlights
Dual antiplatelet therapy forms currently the basis in acute coronary syndrome pharmacological treatment
Clopidogrel given in the CURE study in patients with Acute Coronary Syndrome (ACS) significantly improved the clinical outcome compared with patients treated with aspirin alone [1]
There is a wide variability in antiplatelet response to clopidogrel, which may lead to antiplatelet therapy insufficient efficacy and subsequent risk of thrombotic events
Summary
Dual antiplatelet therapy forms currently the basis in acute coronary syndrome pharmacological treatment. To the Editor: Dual antiplatelet therapy containing aspirin and ADP receptor antagonist forms currently the basis in Acute Coronary Syndrome (ACS) pharmacological treatment. The introduction of ADP receptor antagonists has made a major advance in the ACS treatment. There is a wide variability in antiplatelet response to clopidogrel, which may lead to antiplatelet therapy insufficient efficacy and subsequent risk of thrombotic events.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
